Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

GE Healthcare Strengthens R&D Efforts in Alzheimer’s Disease

Published: Friday, April 13, 2012
Last Updated: Friday, April 13, 2012
Bookmark and Share
A Research Collaboration with Clino Ltd., a biotechnology venture from Tohoku University on the development of novel Tau imaging tracers.

Collaboration aims to increase the accuracy of pre-symptomatic diagnoses, and discover pharmaceuticals for PET exams and contributing to new treatments on the molecular level.

GE Healthcare (Chalfont St. Giles, U.K.; John Dineen, president and CEO), Medical Diagnostics business has entered into research collaboration with Clino Ltd. (Sendai, Miyagi Prefecture; Noriaki Satake, president), a venture by Tohoku University to discover in vivo imaging tracers for tau proteins that accumulate in the brains of Alzheimer’s Disease patients.

Yukitsuka Kudo, head of imaging at Clino and a professor at Tohoku University Innovation of New Biomedical Engineering Center, explains the significance of the research project: “The development of radiotracers for tau examinations involves a number of hurdles, and we’re hoping that our joint research with GE’s worldwide operation will enable us to serve as a bridge that will speed the further evolution of these pharmaceuticals, as well as their progression through clinical and therapeutic trials.”

Professor Hiroyuki Arai of the Institute of Development, Aging and Cancer at Tohoku University is the leading domestic researcher on Alzheimer’s and the first person in the world to succeed in detecting tau proteins in cerebrospinal fluid and argue for their significance as surrogate biomarker. Dr. Arai stresses the crucial nature of tau imaging in Alzheimer’s diagnoses: “Research data on PET imaging of amyloid are currently being accumulated, and the thinking now is that if we can conduct additional tau PET imaging on healthy subjects who have tested positive in amyloid PET exams, it will become possible to identify those with high risk of converting to Alzheimer’s. This could lead to diagnoses of pre-clinical stage Alzheimer’s disease’, which may enable prevention before the onset of symptoms.”

As of 2010, there were a total of approximately 35.6 million confirmed cases of Alzheimer’s disease worldwide, and projections indicate that the total will reach 115.4 million cases by 2050.(1) In Japan, which is leading the world in terms of the advance of population aging, there were approximately 2 million cases in 2010, with a projected 3.25 million expected by 2020(2). Alzheimer’s is thought to be caused by accumulations within the brain of beta amyloid and tau proteins. Beta amyloid plaques are thought to begin accumulating within the brain 30 years before symptoms appear, and tau proteins ten years prior.

“The collaboration we are announcing today is part of our ongoing effort to understand and identify Alzheimer’s disease in its very early stages,” said Pascale Witz, CEO of GE Healthcare Medical Diagnostics. “The combination of our different business offerings positions us well to offer an integrated global diagnostics solution for the next generation of therapies. We are working with pharma to understand their strategic needs and design solutions accordingly.”

GE Healthcare already provides the worldwide supply of (11)C-PIB, a PET contrast agent for beta amyloid detection developed by the University of Pittsburgh in 2003 and for which GE Healthcare has obtained exclusive rights of utilization. In addition, if the new joint venture with Clino results in the identification of agents that can distinguish tau accumulation, it will become possible to diagnose the level of severity of Alzheimer’s symptoms. It would also be expected to enable the development of drugs by the pharmaceutical industry and research institutes that would target tau proteins on the molecular level.

Further, GE Healthcare and Clino will consider collaborations with other companies and research institutes developing tau protein therapies. These are among the many efforts aimed at contributing to the early, precise diagnosis and treatment of Alzheimer’s.

In addition to development of pharmaceuticals, GE Healthcare is currently providing diagnostic imaging devices such as PET and magnetic resonance imaging (MRI) scanners in support of the detection of cognitive diseases including Alzheimer’s. They have also been supporters from the outset of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a clinical observational research project designed to generate standards for Alzheimer’s diagnosis and assessment of the degree to which the disease has progressed. They are moving ahead with a diverse range of efforts toward the imaging evaluation of cognitive diseases around the world including in Japan.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing
The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types.
Tuesday, September 30, 2014
GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
GE Healthcare Acquires Unisyn Medical Technologies’ Transactional Business
The proprietary products and services from Unisyn will be integrated into GE Healthcare’s Global Services organization.
Thursday, May 30, 2013
GE Healthcare Completes Acquisition of SeqWright, Inc., Expanding Capabilities in Fast Growing Molecular Diagnostic Segment
Addition of high growth company builds on Clarient’s biopharma service capabilities and provides platform to offer sequencing-based clinical diagnostics in the future.
Thursday, April 05, 2012
GE Healthcare and M+W Group Form Strategic Alliance in Vaccines, Insulin and Biopharmaceuticals
Companies to help emerging nations develop their own manufacturing capabilities for essential biopharmaceuticals, reducing reliance on imports.
Wednesday, December 14, 2011
GE Healthcare to Invest $1 Billion in New Oncology Solutions
Expanding advanced cancer diagnostic and molecular imaging capabilities.
Saturday, September 17, 2011
GE Healthcare Appoints Kieran Murphy as Life Sciences CEO, Successor to Peter Ehrenheim
On 1 April 2011, Kieran Murphy will be promoted to succeed current Life Sciences President and CEO Peter Ehrenheim who will retire from GE after a transition period on July 31 2011.
Tuesday, February 22, 2011
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos